TTP399 clinical trials
Also written TTP399.
How each study uses TTP399 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TTP399 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
vTv Therapeutics (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test TTP399, phase 3 first.
- Apr 2027Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesPhase 3 · vTv Therapeutics
- Jun 2027Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) SystemsPhase 2 · vTv Therapeutics
Studies
Open first, then newest update. How each study uses TTP399 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) SystemsRecruitingPhase 2vTv TherapeuticsNCT07616206Written as Cadisegliatin 800 mg QD
- Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesActive, not recruitingPhase 3vTv TherapeuticsNCT06334133Written as Cadisegliatin 800 mg QD
- Evaluation of TTP399 in Patients With Type 1 DiabetesCompletedPhase 1/2vTv TherapeuticsNCT03335371Written as TTP399
- Add Glucokinase Activator to Target A1cCompletedPhase 2vTv TherapeuticsNCT02405260Written as TTP399 400 mg
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Codes
What other systems call TTP399 · ClinicalTrials.gg INT001201
- MeSH (NLM) C000654432TTP399One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000654432 | TTP399 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.